Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Concerta Approved for ADHD, Depression Deleted as Indication for Ritalin
November 12, 2007
- Eisai: Record-High Sales, Profits Driven by Aricept
November 12, 2007
- JMA Calls For Reimbursement of Generics Used Off-label
November 12, 2007
- Debiopharm Licenses DACH-platin MediCelle from NanoCarrier
November 12, 2007
- Sawai Revises Business Forecasts Downward
November 12, 2007
- Taisho Concludes LOI with Pfizer on TS-032
November 12, 2007
- Different Views Presented on NHI Price Listing for Generics 4 Times a Year
November 12, 2007
- About 80% of Intestinal Flora Species Remain Unknown
November 12, 2007
- Korosho to Promote Elimination of Films from Imaging Diagnosis
November 12, 2007
- 11 Generics Receive NHI Price Listing in the 1st Biannual Listing
November 12, 2007
- Pfizer Japan Begins Restructuring to Spur Simultaneous Global Development
November 12, 2007
- MEDICAL DEVICE NEWS IN BRIEF
November 12, 2007
- BUSINESS NEWS IN BRIEF
November 12, 2007
- STPO PRESS／Prasugrel Significantly Reduces Risk of Serious CV Events Compared to Clopidogrel
November 12, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 12, 2007
- TOPICS 2 articles
November 12, 2007
- Chugai to Place Top Priority on Proper Use of Tarceva
November 5, 2007
- Telavancin Received FDA Approvable Letter: Astellas
November 5, 2007
- Chugai's Operating Profits Up 24% in First 3 Qtr
November 5, 2007
- Nexavar, Zevalin, Gracevit, Prezista Recommended for Approval
November 5, 2007
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…